New England Journal of Medicine Under Review: What the Status Means
If your New England Journal of Medicine manuscript shows Under Review, here is what the editor and reviewers are likely doing and when to follow up.
While you wait
Waiting on NEJM? Get your next move ready.
The NEJM wait is out of your hands; the next move isn't. Scan your next manuscript free, or run this paper through the scan to see what reviewers typically push back on, so the revision response is ready when the decision lands.
Last reviewed: 2026-10-08.
Quick answer: If your New England Journal of Medicine manuscript shows Under Review, it usually means the paper has moved beyond file intake into editor routing, reviewer invitation, active review, late reviewer reports, or editor synthesis.
Read the status through the stages NEJM describes: initial in-house review is typically completed in less than one week, peer reviewers typically report within one to two weeks, and NEJM publishes no timing for later steps or a follow-up threshold. As our own practical rule, 4 to 6 weeks if a rapid review request or initial editorial window has passed without movement, and 8 to 10 weeks after confirmed external review if the status is static is a reasonable follow-up threshold if nothing has changed.
For a paper-level read before the decision arrives, run a New England Journal of Medicine manuscript readiness check.
Submission portal and editorial contact: New England Journal of Medicine status should be checked in the official portal or author path at NEJM online submission system. For editorial-office or platform questions, use editorial@nejm.org. Use the NEJM online submission system or the author-center contact path for manuscript-specific status questions.
The best public status-interpretation sources are NEJM journal page, NEJM journal page, NEJM online submission system, NEJM journal page, NEJM Group leadership page.
New England Journal of Medicine status dictionary
Status | What it usually means | Typical duration |
|---|---|---|
Submitted | The manuscript, proposal, inquiry, or invited article is uploaded through the official journal submission path | NEJM publishes no timing |
Initial checks | NEJM says each manuscript is checked on submission to determine whether the study needed trial registration and, if registered, whether the registration is complete and meaningful; no manuscript enters the editorial process until it passes this screen | NEJM publishes no timing |
With editor | The Executive Editor reviews each research submission (about 10% are declined at this stage) and an associate editor judges quality, novelty, and potential clinical impact | Initial in-house review is typically completed in less than one week |
Under Review | Reviewers are being invited, actively reviewing, or reports are being synthesized | In almost all cases, two peer reviewers evaluate each submission within one to two weeks |
Reviews complete | Reports are in and associate editors decide whether to decline or bring the paper to a weekly editorial meeting | NEJM publishes no timing |
Decision in process | The decision letter, transfer option, editor response, proposal answer, or revision request is being prepared | NEJM publishes no timing |
NEJM publishes timing for only two stages: initial in-house review (typically under one week) and peer review (typically one to two weeks). The status meanings above are planning aids for authors deciding whether to wait, prepare a revision, or send a status inquiry, not promises of timing.
File intake and editorial-office checks
The first status period is not the full scientific review. NEJM says its Executive Editor reviews each research manuscript to decide whether it warrants further consideration and peer review, and that each manuscript is checked on submission for trial registration where it applies. A complete record helps: files open correctly, author metadata is complete, ethics statements are present, and the manuscript matches the journal's scope. For New England Journal of Medicine, this stage matters because a small administrative issue can look like a peer-review delay from the author's side.
An early status change signals routing, not a full reviewer roster.
The useful action during this stage is not to ask whether the editor likes the paper. It is to get the record and the paper saying the same thing. A mismatch between the cover letter, abstract, figure sequence, methods, data, or supplementary files creates editorial friction even when the work is credible.
For New England Journal of Medicine, the file package should make clear that the manuscript is about NEJM submission-system intake, title page, structured abstract, protocol, statistical analysis plan, trial registration, IRB or ethics approval, ICMJE disclosures, funding statement, data-sharing plan, figure and table package, and cover-letter context rather than a generic manuscript looking for a prestigious home before a reviewer has to reconstruct the claim.
Editor routing
At this point the manuscript is being read for fit. The editor is not only asking whether the manuscript is polished, but whether the manuscript makes practice-change threshold, primary endpoint visibility, effect size, harms and safety reporting, protocol-to-manuscript alignment, statistical review readiness, and routing against JAMA, The Lancet, BMJ, Annals of Internal Medicine, Nature Medicine, and specialty clinical journals visible quickly enough to justify outside review.
A manuscript can be technically careful and still difficult to route if the abstract promises one contribution while the methods, figures, data, or supplementary files support another.
The editor may be matching the manuscript to clinical specialty reviewers, trialists, biostatisticians, epidemiologists, ethics or safety reviewers, and NEJM statistical editors. That matching process can take time because the editor needs reviewers who can evaluate the central claim without rebuilding the manuscript's logic from scratch. The same label covers reviewer recruitment and active review alike.
At New England Journal of Medicine, the handling editor is usually testing practice-change threshold, primary endpoint visibility, effect size, harms and safety reporting, protocol-to-manuscript alignment, statistical review readiness, and routing against JAMA, The Lancet, BMJ, Annals of Internal Medicine, Nature Medicine, and specialty clinical journals.
The portal can show Under Review while the handling editor reads the title page, structured abstract, protocol, statistical analysis plan, trial registration, IRB or ethics approval statement, data-sharing plan, and figure and table package.
That editorial culture matters because a strong manuscript can still fail if the review path makes it look like the wrong article type, audience, or venue.
A New England Journal of Medicine handling editor is also deciding whether the paper should stay in this exact journal lane or route to JAMA, The Lancet, BMJ, Annals of Internal Medicine, Nature Medicine, JAMA Internal Medicine, NEJM Evidence, The Lancet specialty journals, and high-fit specialty clinical journals before the full reviewer pool is assembled.
Parallel reviewer search and scope checks
In parallel, the editor may be identifying at least two reviewers and checking whether the manuscript has the right scope for those reviewers. Recruiting reviewers can take time when the topic sits between fields, depends on a specialized dataset, or requires both methodological and domain expertise. A New England Journal of Medicine manuscript can therefore show Under Review while the editor is still securing the right reviewer mix.
For authors, the useful question is not "has someone accepted yet?" The useful question is "if a reviewer accepts today, would the manuscript's NEJM submission-system intake, title page, structured abstract, protocol, statistical analysis plan, trial registration, IRB or ethics approval, ICMJE disclosures, funding statement, data-sharing plan, figure and table package, and cover-letter context make the claim easy to evaluate?" That is the difference between passive waiting and productive waiting.
Active review
This is the main period in which reviewers evaluate the paper. They are usually checking whether the conclusion follows from the methods, whether the strongest comparison or control is present, whether figures match claims, and whether limitations are honest. In New England Journal of Medicine, the common weak point is not always the headline finding. It is often the missing bridge between the manuscript's strongest claim and the evidence a reviewer can audit quickly.
Active review is also where timeline anxiety becomes least informative. A quiet portal does not tell you whether one reviewer is late, whether the editor is waiting for another report, whether a reviewer declined and had to be replaced, or whether reports are already in synthesis. NEJM says peer reviewers typically report within one to two weeks and publishes no total active-review window; rapid-review manuscripts move faster (NEJM says an initial decision on a Rapid Review typically comes within two weeks), and statistical review after Revision status adds time.
Use the waiting window to produce a revision-ready response map. Put the likely objection in one column, the manuscript location in another, the strongest supporting figure or table in a third, and the limitation language in a fourth. If the decision is revise, that map saves days. If the decision is reject, it helps you choose a cleaner transfer or resubmission path.
Editor synthesis
After reports arrive, the editor has to turn them into a decision. This can still look like Under Review, Reviews Complete, Required Reviews Complete, Awaiting Recommendation, or Decision in Process depending on the portal. Do not assume silence during this period means rejection. It can mean the editor is reconciling mixed reports, checking whether one reviewer misunderstood the scope, or deciding whether the manuscript needs another opinion.
The synthesis window is where the editor tests whether reviewer concerns are compatible. If one reviewer wants deeper methods and another wants a shorter argument, the decision letter may take longer because the editor has to decide which instruction governs the revision. That delay is procedural, not necessarily negative.
What to do: when to follow up
Do not send a status inquiry during the normal early window. Asking too soon adds friction and changes nothing. Use this threshold instead:
- In the first one to two weeks: wait unless the portal asks for files or an ethics issue appears.
- After that, until your follow-up threshold: assume reviewer invitation, active review, or editor synthesis is happening.
- At 4 to 6 weeks if a rapid review request or initial editorial window has passed without movement, and 8 to 10 weeks after confirmed external review if the status is static (our practical rule; NEJM publishes no follow-up threshold): send one concise inquiry with manuscript ID, title, current status, and submission date.
- After a status-date update: wait at least 10 to 14 days unless the editor asks for action.
The best message is operational, not anxious. Ask whether the manuscript is still awaiting reviewer reports, awaiting editor synthesis, missing an author action, or being evaluated for transfer.
Readiness check
While you wait on NEJM, scan your next manuscript.
The scan takes about 2 to 3 minutes. Use the result to decide whether to revise before the decision comes back.
"My paper has been Under Review for 12 weeks. Is that bad?"
Not automatically. The most common explanation is reviewer recruitment or a delayed report, not a hidden rejection. The more useful reading is whether elapsed time matches the stage: NEJM says peer reviewers typically report within one to two weeks and publishes no total active-review window. If the paper moved to Under Review quickly and then stayed there, the editor may still be waiting on one reviewer. If it changed after several weeks, the editor may be in synthesis. If there has been no movement past the normal threshold, a polite inquiry is reasonable.
What you should not do is rewrite the manuscript in panic or submit elsewhere. Prepare the response materials that will matter if the decision is revise, reject with comments, or transfer.
What to prepare while New England Journal of Medicine is Under Review
Reviewer focus | Why it matters at New England Journal of Medicine | How to prepare |
|---|---|---|
New England Journal of Medicine practice-change claim | reviewers need the manuscript to make this claim auditable without reconstructing the authors' intent. | Build the answer around NEJM submission-system intake, title page, structured abstract, protocol, statistical analysis plan, trial registration, IRB or ethics approval, ICMJE disclosures, funding statement, data-sharing plan, figure and table package, and cover-letter context. |
New England Journal of Medicine protocol and SAP alignment | reviewers need the manuscript to make this claim auditable without reconstructing the authors' intent. | Build the answer around NEJM submission-system intake, title page, structured abstract, protocol, statistical analysis plan, trial registration, IRB or ethics approval, ICMJE disclosures, funding statement, data-sharing plan, figure and table package, and cover-letter context. |
New England Journal of Medicine harms and safety package | reviewers need the manuscript to make this claim auditable without reconstructing the authors' intent. | Build the answer around NEJM submission-system intake, title page, structured abstract, protocol, statistical analysis plan, trial registration, IRB or ethics approval, ICMJE disclosures, funding statement, data-sharing plan, figure and table package, and cover-letter context. |
New England Journal of Medicine primary endpoint map | reviewers need the manuscript to make this claim auditable without reconstructing the authors' intent. | Build the answer around NEJM submission-system intake, title page, structured abstract, protocol, statistical analysis plan, trial registration, IRB or ethics approval, ICMJE disclosures, funding statement, data-sharing plan, figure and table package, and cover-letter context. |
New England Journal of Medicine general-medicine routing fit | reviewers need the manuscript to make this claim auditable without reconstructing the authors' intent. | Build the answer around NEJM submission-system intake, title page, structured abstract, protocol, statistical analysis plan, trial registration, IRB or ethics approval, ICMJE disclosures, funding statement, data-sharing plan, figure and table package, and cover-letter context. |
New England Journal of Medicine valid result without practice change | the study is methodologically credible but the effect size, endpoint, clinical action, or patient-burden argument does not make a general physician behave differently. Prepare a one-page practice-change map tied to the abstract, endpoint table, figure sequence, safety table, and discussion limitations. | Prepare a one-sentence location map naming the manuscript component, figure, method, dataset, limitation, or response block that answers it. |
New England Journal of Medicine protocol or SAP mismatch | the manuscript tells a cleaner story than the dated protocol, statistical analysis plan, registration record, or amendment history supports. During Under Review, reconcile the primary endpoint, population, subgroup analyses, exclusions, and sensitivity analyses before a statistical editor forces the issue. | Prepare a one-sentence location map naming the manuscript component, figure, method, dataset, limitation, or response block that answers it. |
New England Journal of Medicine benefits clearer than harms | the abstract foregrounds efficacy while adverse events, patient burden, discontinuation, quality of life, or competing risks sit in supplementary material. Prepare a balanced benefit-to-burden answer because NEJM reviewers often treat safety visibility as part of clinical significance. | Prepare a one-sentence location map naming the manuscript component, figure, method, dataset, limitation, or response block that answers it. |
Reporting checklists and study-design signals
For New England Journal of Medicine, reporting discipline means a CONSORT-format flow diagram for trials, trial registration, protocol, SAP, financial disclosures, IRB or ethics approval statements, data-sharing plan, quantitative adverse-event reporting, and editable vector files for data visualizations.
PRISMA can matter for synthesis work, STROBE can matter for observational datasets, ARRIVE can matter for animal work, CONSORT can matter for trials, and field-specific reporting norms can matter when the study design demands them. The recurring New England Journal of Medicine status risk is usually not that authors forgot one checklist name.
It is that the manuscript package does not make the evidence chain visible before the reviewer starts looking for it. If your paper involves human participants, animal experiments, survey instruments, observational datasets, confidential records, computational pipelines, deposited datasets, field experiments, intervention design, systematic literature selection, crystallographic data, or psychological measurement, check the relevant reporting framework before the reviewer asks.
A status page helps because Under Review is the last calm window to align NEJM submission-system intake, title page, structured abstract, protocol, statistical analysis plan, trial registration, IRB or ethics approval, ICMJE disclosures, funding statement, data-sharing plan, figure and table package, and cover-letter context before a decision letter turns those gaps into required work.
Across our pre-submission reviews for New England Journal of Medicine
Across our pre-submission reviews for New England Journal of Medicine manuscript packages, three named patterns explain most of the productive work authors can do while the portal still says Under Review. These patterns are useful because they are tied to manuscript components a reviewer can inspect, not to generic advice about waiting.
Our review of New England Journal of Medicine manuscript packages turns each status-risk pattern below into a concrete waiting-window task: inspect the abstract, first figure or model, methods, cover letter, data files, reporting notes, and limitation language before the reviewer report arrives.
The pages that create the most avoidable status anxiety are not always the obviously weak papers. They are credible papers where authors wait passively during Under Review instead of preparing for the exact review objections most likely to arrive. Official guidance explains the workflow, but it rarely connects the status label to the manuscript components reviewers will test.
- New England Journal of Medicine valid result without practice change: the study is methodologically credible but the effect size, endpoint, clinical action, or patient-burden argument does not make a general physician behave differently. Prepare a one-page practice-change map tied to the abstract, endpoint table, figure sequence, safety table, and discussion limitations.
For New England Journal of Medicine, connect this risk to NEJM submission-system intake, title page, structured abstract, protocol, statistical analysis plan, trial registration, IRB or ethics approval, ICMJE disclosures, funding statement, data-sharing plan, figure and table package, and cover-letter context and to the exact reviewer audience the editor is likely to recruit.
- New England Journal of Medicine protocol or SAP mismatch: the manuscript tells a cleaner story than the dated protocol, statistical analysis plan, registration record, or amendment history supports. During Under Review, reconcile the primary endpoint, population, subgroup analyses, exclusions, and sensitivity analyses before a statistical editor forces the issue.
For New England Journal of Medicine, connect this risk to NEJM submission-system intake, title page, structured abstract, protocol, statistical analysis plan, trial registration, IRB or ethics approval, ICMJE disclosures, funding statement, data-sharing plan, figure and table package, and cover-letter context and to the exact reviewer audience the editor is likely to recruit.
- New England Journal of Medicine benefits clearer than harms: the abstract foregrounds efficacy while adverse events, patient burden, discontinuation, quality of life, or competing risks sit in supplementary material. Prepare a balanced benefit-to-burden answer because NEJM reviewers often treat safety visibility as part of clinical significance.
For New England Journal of Medicine, connect this risk to NEJM submission-system intake, title page, structured abstract, protocol, statistical analysis plan, trial registration, IRB or ethics approval, ICMJE disclosures, funding statement, data-sharing plan, figure and table package, and cover-letter context and to the exact reviewer audience the editor is likely to recruit.
- New England Journal of Medicine reviewer-routing risk: The wrong reviewer pool can make a sound paper look less convincing than it is. Use the waiting window to identify how the abstract, keywords, suggested reviewers, article type, and field framing point to clinical specialty reviewers, trialists, biostatisticians, epidemiologists, ethics or safety reviewers, and NEJM statistical editors.
- New England Journal of Medicine revision-readiness gap: Revision speed depends on whether authors already know which objection is likely. Draft answer blocks for the two most likely reviewer concerns before the decision letter arrives.
The recurring Manusights pattern is that authors often over-prepare the wrong asset while the manuscript is under review. They polish prose when the likely reviewer objection is a missing control, rewrite the introduction when the likely problem is a benchmark table, or wait for the decision letter when the abstract, methods, figures, theory, and supplementary files already reveal the response strategy.
For New England Journal of Medicine, the highest-value waiting work is to make the evidence chain explicit enough that a reviewer can test the claim without inventing the authors' logic.
In our New England Journal of Medicine pre-submission review work, what mattered was never the status text itself. The useful distinction was between drafts with an evidence map already built and drafts without one.
Official guidance explains the workflow, but that is why this page ties Under Review to NEJM submission-system intake, title page, structured abstract, protocol, statistical analysis plan, trial registration, IRB or ethics approval, ICMJE disclosures, funding statement, data-sharing plan, figure and table package, and cover-letter context instead of only defining the status phrase.
If you want a second set of eyes before the report lands, use the New England Journal of Medicine AI review to identify reviewer-risk issues while the manuscript is still under review.
Submit If
- the manuscript is clearly a New England Journal of Medicine contribution, not a generic manuscript using the journal name as a prestige target
- the abstract, first figure, and cover letter make the central claim auditable
- the article type, data package, and limitation language match New England Journal of Medicine's editorial culture
Think Twice If
- the manuscript needs a different article type, audience, or evidence standard to be fairly reviewed
- the central contribution is better suited to JAMA, The Lancet, BMJ, Annals of Internal Medicine, Nature Medicine, JAMA Internal Medicine, NEJM Evidence, The Lancet specialty journals, and high-fit specialty clinical journals
- the paper's strongest claim cannot be located quickly in the abstract, first figure, methods, data files, and limitations
Nearby routes to keep in view
JAMA, The Lancet, BMJ, Annals of Internal Medicine, Nature Medicine, JAMA Internal Medicine, NEJM Evidence, The Lancet specialty journals, and high-fit specialty clinical journals can be cleaner routes when the result needs more length, narrower readership, a different article format, or a different editorial promise. Do not treat transfer planning as pessimism. It is a way to shorten the next move if the decision letter confirms the current venue is one level too broad, too narrow, or too format-specific.
Reader intent and source-fit note
Official pages explain submission mechanics, but they usually do not translate a static Under Review label into the author's next practical move. Publisher resources identify the submission route, journal scope, and author-facing requirements; the Manusights layer interprets the status through New England Journal of Medicine manuscript risk. The reader job is narrow: "my manuscript is already in the portal; what does this status mean and what should I do while waiting?"
The Manusights review link appears only after the status definition, timeline, follow-up threshold, source limitations, and journal-specific reviewer-risk prep. That keeps this status page focused on the waiting author while leaving the public submission guide to own pre-upload mechanics.
Source limitations
Source limitations: this page uses public official-source guidance plus Manusights manuscript-risk interpretation; it cannot see the private reviewer invitations, report status, or handling-editor notes inside your manuscript record.
Public journal guidance can tell you the portal, article-scope language, submission route, and broad peer-review policy. It usually cannot tell you whether your specific paper has reviewers assigned, whether a reviewer has missed a deadline, or whether the editor is leaning toward revision or rejection. That is why this page separates official-source facts from practical interpretation. The official sources anchor the workflow; the Manusights contribution is the manuscript-level risk translation.
Related New England Journal of Medicine pages
Before you wait another month, run a New England Journal of Medicine reviewer-risk check and prepare the revision map reviewers are most likely to force you to build later.
Source-specific notes from this research pass:
- The official publisher pages identify the journal scope, submission route, and author-facing requirements for this status interpretation.
- The official portal or author-instruction page is the source of truth for the manuscript record; this page does not replace private portal status.
- The Manusights layer is the manuscript-risk translation: what to prepare while the status remains static.
Frequently asked questions
New England Journal of Medicine Under Review usually means the manuscript, proposal, or invited article is in editor routing, reviewer invitation, active review, or editor synthesis. Check the official author instructions or the official author route for the live manuscript record.
NEJM says initial in-house review is typically completed in less than one week and that two peer reviewers typically evaluate each submission within one to two weeks. NEJM publishes no total active-review window, rapid-review manuscripts move faster (an initial decision on a Rapid Review typically comes within two weeks), and statistical review after Revision status adds time. NEJM publishes no follow-up threshold; our practical rule is 4 to 6 weeks if a rapid review request or initial editorial window has passed without movement, and 8 to 10 weeks after confirmed external review if the status is static.
Do not email during the normal early window. If the status is unchanged around 4 to 6 weeks if a rapid review request or initial editorial window has passed without movement, and 8 to 10 weeks after confirmed external review if the status is static, send one concise message with the manuscript ID, submission date, current status, and a specific status question to the NEJM Editorial Office at editorial@nejm.org.
The next step is usually reviews complete, decision in process, revision, rejection, transfer, editor decision, proposal response, or production after acceptance. The label by itself does not predict the decision.
Use the official portal or official author instructions. Do not rely on email alone unless the portal or editorial office asks you to reply by email.
Not by itself. Long Under Review time usually points to reviewer recruitment, delayed reports, editor synthesis, commissioning review, or routing complexity. It becomes concerning when it passes 4 to 6 weeks if a rapid review request or initial editorial window has passed without movement, and 8 to 10 weeks after confirmed external review if the status is static without portal movement or editorial-office response.
Sources
Free guide
Waiting is not the same as being ignored, and there is a way to tell.
Reviewers usually get ten days. When it has been months, an appeal and a complaint are different instruments with different addresses, and only one of them fits a delay. This is which to use, and the wording that gets an answer.
Final step
Done interpreting the status? Put the wait to work.
The NEJM decision will arrive on the journal's clock. What you control is what's next: scan your next manuscript free, or run this paper through the scan so the likely reviewer pushback is mapped before the revision request lands.
Free scan, no card needed.
Target journal New England Journal of Medicine
Private API processing. Your manuscript is not used to train models.
Re-read the status guidePut the guidance to work
Turn a decision into a clear next step.
Use the practical response workflow when a manuscript needs revision, or the process guide when you need to understand what the editorial status means.